Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265)

Navigation

Article	Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0) (DOI: 10.1080/22221751.2020.1735265)
Sections in this Publication
Section	Section 1: Introduction (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 2: Protection requirements of medical personnel (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 2.1: Selection of front-line personnel (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 2.2: Isolation and protection requirements (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 2.3: Isolation and observation of medical personnel after close contact with SARS-CoV-2 (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3: Diagnosis and treatment of SARS-CoV-2 infected patients (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.1: Screening criteria (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.2: Diagnostic criteria (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.3: Examination routines of SARS-CoV-2 infected patient (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.3.1: Screening cases on the day of visit (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.3.2: Sequential examination of confirmed patients (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.4: Place of treatment according to the severity of the disease (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.4.1: Severe type (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.4.2: Critically ill type (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.5: Treatment (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.5.1: General treatment (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.5.2: Oxygen therapy (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.5.2.1: Choice of oxygen therapy (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.5.2.2: The way of respiratory support (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.5.5: Intravenous immunoglobulin (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265)
Section	Section 5: Criteria of isolation release and discharge (from DOI: 10.1080/22221751.2020.1735265)
Named Entities in this Section

From publication: "Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0)" in the journal Emerg Microbes Infect (2020)
https://doi.org/10.1080/22221751.2020.1735265

Section 3.5.3: Antiviral treatment

Currently, there is no evidence to support the effectiveness of existing antiviral drugs against SARS-CoV-2. Lopinavir/ritonavir can be used when appropriate, 2 tablets, twice daily for 14 days.

Go to next section in publication